摘要
目的探讨不同浓度皮下注射硼替佐米对多发性骨髓瘤患者的疗效及不良反应。方法选取2017年9月~2018年12月入住血液病科多发性骨髓瘤患者80例,入院后根据皮下注射硼替佐米浓度不同将患者分为两组,2.5 mg/ml组(40例)和1.0 mg/ml组(40例)。观察注射局部红肿、硬结、疼痛、神经毒性等不良反应。结果2.5 mg/ml组在引起局部红肿、硬结、疼痛等不良反应方面明显低于1.0 mg/ml组,两组比较差异有统计学意义(P<0.01)。在神经毒性方面两组比较,差异无统计学意义(P>0.05)。结论皮下注射浓度为2.5 mg/ml可减少多发性骨髓瘤患者局部损伤,且不改变硼替佐米疗效。
Objective To compare the efficacy and adverse reactions of subcutaneous injection of bortezomib at different concentrations in patients with multiple myeloma.Methods About 80 patients admitted to the hematology department with multiple myeloma treated with bortezomib from September 1,2017 to December 31,2018 were divided into two groups and received subcutaneous injections of bortezomib at 2.5 mg/ml or 1.0 mg/ml according to their group.local redness,induration,pain,neurotoxicity and other adverse reactions were observed to evaluate the effects of injection at different concentrations.Results Patients received bortezomib at 2.5 mg/ml were significantly less likely to suffer from local swelling,induration or pain compared with their counterpart(P<0.01).While there was no significant difference in neurotoxicity between the two groups.Conclusion Subcutaneous injection of bortezomib at 2.5 mg/ml can reduce the risk of local injury in patients with multiple myeloma without decreasing the efficacy of bortezomib.
作者
董丽丽
胡燕红
唐菊英
朱海燕
Dong Lili;Hu Yanhong;Tang Juying(Department of Hematology,the First Medical Center of Chinese PLA General Hospital,Beijing 100853,China)
出处
《中华保健医学杂志》
2020年第2期150-152,共3页
Chinese Journal of Health Care and Medicine
基金
解放军总医院临床科研扶持基金资助项目(2017FC-TSYS-2039)。
关键词
多发性骨髓瘤
硼替佐米
皮下注射
不同给药浓度
multiple myeloma
bortezomib
subcutaneous injection
different concentrations
